Time to read
1 minute
Read so far

Patients with colorectal peritoneal metastasis may benefit from immunotherapy treatment

Wed, 11/04/2020 - 15:57
Posted in:

A study from the University of Birmingham has found that 50% of patients with colorectal peritoneal metastasis (CPM), a rare type of cancer that has spread into the lining of their abdomen (peritoneal cavity), may be suitable for immunotherapy treatment.

Unfortunately for around 1% of bowel cancer patients and this type of spread in bowel cancer patients carries a very poor prognosis and so most patients do not survive beyond 12 months from diagnosis. Patients with CPM have a limited survival rate with the best available treatments. Conventional chemotherapy is ineffective and current treatment consists of extensive surgery which does not always work.

This first of its kind study, ‘The transition from primary colorectal cancer to isolated peritoneal malignancy is associated with an increased tumour mutational burden’, published in Scientific Reports and funded by Good Hope Hospital Charity, found that understanding the tumour biology may identify which patients with bowel cancer are at risk of developing CPM. By identifying the specific tumour biology of this groups of patients, they carry a specific mutation that makes them sensitive to immunotherapy.

"We have found that approximately 50% of patients with CPM have a type of genetic change, called hypermutation. This means they may be sensitive to immunotherapy as this type of treatment has good results in other patient groups with hypermutations,” explained lead author, Professor Andrew Beggs from the University of Birmingham's Institute of Cancer and Genomic Sciences. "We also found potential sensitivity to a drug called a Porcupine inhibitor, based on another genetic marker identified in these patients. This is the first study of its kind in the world for patients with CPM, and our results have shown this could provide a potentially curative option for patients given the responses we have seen to immunotherapy in other cancers."

Researchers will now look to set up an international clinical trial to examine the use of immunotherapy for patients with CPM.

To access this paper, please click here